Thursday, October 17, 2019 - 08:30

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“Innate” or the “Company”), a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need, announces that trading of its ordinary shares on the regulated market of Euronext in Paris (“Euronext Paris”) will be halted, at the Company’s request, from the opening of the market at 9:00 AM CEST. This trading halt takes place in the context of the initial public offering of the Company on the Nasdaq Global Select Market, the terms of which have been previously announced today, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market.

This trading halt will continue until the closing of Euronext Paris today and trading will resume at the opening of Euronext Paris at 9:00 AM CEST on October 18, 2019.

PR in English94.19 KB
CP en français68.58 KB